Leveraging the "absurd revolution in DNA sequencing costs" over the past decade, the San Francisco-based firm is developing an assay for interrogation of the immune repertoire.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.